The Emerging Role of Metabolic Health in Male Breast Cancer Research
Reflections Following a Strategic Meeting Between the Male Breast Cancer Global Alliance and Emory University
By Lennard M. Goetze, Ed.D. / Dr. Robert Bard
Executive Director, AngioInstitute
On June 10, 2026, representatives of the Male Breast Cancer Global Alliance (MBCGA) met with
Dr. Neil M. Iyengar, MD, breast medical oncologist, physician-scientist, and Director of Survivorship Services at Emory University's Winship Cancer Institute. The meeting was organized by
Cheri Ambrose, CEO of the Male Breast Cancer Global Alliance, as part of the organization's continuing effort to engage leading investigators whose work has the potential to influence the future direction of breast cancer research, survivorship, and patient-centered care.
Participants included Dr. Robert L. Bard, Chief Clinical Advisor to MBCGA; Daniel Root, Associate Director of Communications; and Lennard M. Goetze, Ed.D., representing the AngioInstitute and its affiliated research and publishing initiatives. The primary purpose of the meeting was to discuss emerging research priorities in breast oncology, explore opportunities for collaborative investigation, and formally invite Dr. Iyengar to join the Medical Advisory Board of the Male Breast Cancer Global Alliance.
The invitation was motivated not only by Dr. Iyengar's clinical expertise, but also by his increasingly influential body of work examining the relationship between metabolic health, lifestyle factors, and cancer outcomes.
Expanding the Framework of Breast Cancer Research
Traditional oncology has historically focused on the biological characteristics of tumors themselves. Increasingly, however, researchers are recognizing that tumor behavior cannot be fully understood without examining the physiologic environment in which malignancies develop and progress.
Dr. Iyengar's research program reflects this broader perspective. During the discussion, he described his work as focusing on "the intersections of metabolic health and lifestyle with both cancer risk and cancer outcomes."
His investigations examine the role of obesity, insulin signaling, inflammation, adipose tissue biology, and body composition in cancer development and survivorship. These factors collectively influence what researchers increasingly describe as the tumor microenvironment—a dynamic ecosystem that may either promote or suppress malignant progression.
As Dr. Iyengar explained, most breast cancers arise within tissue environments dominated by adipose tissue. Consequently, the metabolic state of the individual becomes clinically relevant. "Most breast tumors arise within a microenvironment that's predominantly comprised of fat cells," he noted. "Poor metabolic health and states of energy imbalance can change the tumor microenvironment in a way that supports tumor growth."
This line of investigation has significant implications for both prevention and survivorship. It suggests that interventions directed toward metabolic optimization may ultimately complement conventional treatment strategies by modifying biological conditions associated with disease progression.
From Survivorship to Prevention
Among Dr. Iyengar's most significant contributions has been his leadership in survivorship medicine. As Director of Survivorship Services at Winship Cancer Institute, he oversees the development and integration of evidence-based programs designed to address the long-term needs of cancer survivors. These initiatives extend beyond traditional follow-up care and incorporate nutrition, exercise, supportive care, behavioral interventions, and lifestyle modification.
His previous work at Memorial Sloan Kettering Cancer Center resulted in the development of the Healthy Living Program, an innovative survivorship model designed to create individualized wellness strategies for patients during and after cancer treatment.
Such efforts reflect a growing recognition that survivorship should not be viewed merely as the period following treatment. Rather, survivorship represents a continuum of care that begins at diagnosis and extends throughout the patient's lifespan.
This philosophy aligns with an expanding body of literature demonstrating that exercise, nutrition, body composition, and metabolic regulation may influence recurrence risk, treatment tolerance, quality of life, and overall survival.
Relevance to Male Breast Cancer
Although the majority of breast cancer research understandably focuses on women, male breast cancer remains an area of considerable unmet need. The rarity of the disease presents challenges for investigators seeking to conduct adequately powered studies. Consequently, many clinical recommendations for men are extrapolated from data generated in female populations.
Dr. Iyengar emphasized that such extrapolations may overlook important biological differences. "I have treated and still treat a lot of men with breast cancer," he stated. "The metabolic status of a male versus a post-menopausal female, for example, is very, very different."
This observation has substantial implications for future research. Differences in hormonal physiology, body composition, adipose tissue distribution, and metabolic regulation may influence both disease development and treatment response.
Accordingly, Dr. Iyengar noted that there is a need to examine these questions directly within male populations. "I really think that there's a need to study metabolic health specifically in men." His comments highlight a growing opportunity within male breast cancer research: the development of biologically informed investigations that move beyond simple adaptation of female-centered models.
Challenges in Rare Disease Research
The conversation also addressed one of the most persistent barriers facing male breast cancer investigators: patient recruitment. Dr. Iyengar described a prior research concept involving male breast cancer patients that encountered practical limitations because of anticipated accrual challenges.
"We thought the grant would be criticized for the ability to accrue 40 male breast cancer patients within two years at a single center." This challenge is not unique to male breast cancer. Rare diseases frequently require multi-institutional collaboration to achieve meaningful sample sizes.
The discussion therefore shifted toward opportunities for national recruitment networks, collaborative publishing initiatives, and multi-center research models capable of supporting future investigations. In this regard, the Male Breast Cancer Global Alliance serves an important function by connecting researchers, advocacy organizations, clinicians, survivors, and healthcare systems that may otherwise operate independently.
Survivorship Resources for Men
A particularly important observation emerged regarding survivorship programming. Dr. Iyengar noted that many existing exercise and wellness initiatives remain primarily designed around female breast cancer populations.
"A lot of the lifestyle programs for breast cancer—the diet and exercise programs—are really geared towards women," he explained. While these programs provide substantial value, their design may unintentionally limit engagement among male survivors. This observation reinforces the need for educational resources, rehabilitation programs, exercise interventions, and survivorship models specifically developed for men diagnosed with breast cancer.
As survivorship continues to evolve as a discipline, such considerations may become increasingly important components of comprehensive care.
Appointment to the Medical Advisory Board
Following discussion of these topics, Cheri Ambrose formally invited Dr. Iyengar to join the Medical Advisory Board of the Male Breast Cancer Global Alliance. The invitation reflects recognition of his scholarly contributions to breast oncology, his leadership in survivorship medicine, and his commitment to advancing understanding of the relationship between metabolic health and cancer outcomes.
Dr. Iyengar accepted the invitation, expressing interest in participating in future educational and research initiatives. His appointment adds an important perspective to the advisory board, particularly in areas involving lifestyle medicine, survivorship science, metabolic health, and translational oncology.
Conclusion
The June 10 meeting highlighted several themes that are likely to influence the next generation of breast cancer research: precision lifestyle interventions, survivorship science, metabolic health, collaborative investigation, and the unique needs of men diagnosed with breast cancer.
Dr. Neil M. Iyengar's work occupies a strategic position at the intersection of these emerging disciplines. His research challenges investigators to look beyond the tumor itself and consider the broader biological, behavioral, and metabolic factors that shape cancer outcomes.
For the Male Breast Cancer Global Alliance, the addition of Dr. Iyengar to its Medical Advisory Board represents an opportunity to strengthen scientific dialogue surrounding an often-overlooked patient population. More importantly, it reflects a shared commitment to advancing evidence-based approaches that improve prevention, treatment, survivorship, and quality of life for individuals affected by breast cancer.
As male breast cancer research continues to mature, collaborative relationships between clinicians, scientists, advocacy organizations, and survivors will become increasingly essential. The June 10 discussion represents one step in that process and underscores the value of bringing together diverse expertise in pursuit of common goals.
-----------------------------------------------------------------------------------------------------------------------------
Three Decades of Progress: How Cancer Care Has Been Transformed
By: Bob Ritter
Bob Riter brings the rare perspective of someone who has lived through—and helped shape—three decades of cancer advocacy. In this compelling reflection, he explores the extraordinary evolution of cancer care, from the era of one-size-fits-all chemotherapy to today's precision medicine, targeted therapies, immunotherapy, and personalized treatment strategies. With insight drawn from years of attending leading research conferences, Riter explains how science continues to redefine what is possible while improving both outcomes and quality of life. His inspiring look back reminds us that every breakthrough builds hope for the next generation of patients and survivors.
SEE COMPLETE FEATURE
Advancing Research. Empowering Advocates. Changing the Future of Male Breast Cancer.
The Male Breast Cancer Global Alliance (MBCGA) Research Committee is where science, patient advocacy, and collaboration come together to accelerate progress against male breast cancer. Committed to evidence-based decision-making, the committee serves as a trusted voice in evaluating emerging research, supporting promising scientific initiatives, and ensuring that the unique needs of men with breast cancer are represented throughout the research process.
Committee members work alongside leading investigators, pharmaceutical trial teams, clinicians, and advocacy organizations to review research proposals, contribute valuable patient perspectives, promote educational programs, and mentor the next generation of research advocates. The committee also helps ensure that MBCGA educational resources remain aligned with the latest scientific evidence while encouraging greater participation in nationally recognized advocacy training programs.
Whether you are a survivor, caregiver, healthcare professional, or advocate passionate about advancing research, the MBCGA Research Committee offers a meaningful opportunity to make a lasting impact. By connecting lived experience with scientific discovery, the committee is helping shape better treatments, stronger collaborations, and a brighter future for every man affected by breast cancer. Together, we can transform advocacy into action and research into hope.
I was diagnosed with breast cancer thirty years ago and I’ve attended dozens of national cancer research conferences since then. It’s a useful exercise to step back from time to time and look at the big picture. What’s changed in our understanding of cancer and cancer treatment in those three decades? (Note that this article isn’t specific to male breast cancer). Here are some of the broad themes-
We’ve slowly evolved from thinking that the most aggressive cancer treatment is always the best cancer treatment. I’ve seen this in the surgical removal of axillary lymph nodes. Thirty years ago, it was common to have a complete axillary dissection as a routine part of any mastectomy or lumpectomy. A few years later, sentinel lymph node dissection became the standard of care and additional nodes were removed only if the sentinel nodes were positive. More recently, it’s been discovered that removing a small number of positive nodes does not provide additional benefit and a complete axillary dissection is only performed if there’s extensive axillary involvement. We increasingly realize that less treatment is often better treatment.
